The TRIIM Trial Blueprint: Can we actually reverse biological age?

Introducing the TRIIM Protocol. You’ve optimized your training split, dialed in your macros, and built a recovery stack most coaches would envy. But here’s a question most gym routines never touch: what if your cells are aging faster than your calendar says you are? What if the engine under the hood is running years older than the odometer reads? Enter the epigenetic clock — and the landmark study that dared to ask whether we can turn it back.

This is Part 1 of a three-part series on biological age reversal. Here, we break down the TRIIM trial — the science, the protocol, and the skepticism it deserves. Because before you start chasing reversal, you need to understand what was actually measured, and what the data can and cannot tell you.

KYLE HANSEN FITNESS

Part 1 of 3: The Biological Age Series

What Is the Epigenetic Clock?

The aging research world has been quietly undergoing a revolution — not in a gym, not in a supplement aisle, but in molecular biology labs studying something most lifters have never heard of: epigenetic methylation patterns.

Epigenetic methylation — think of it as chemical bookmarks that sit on top of your DNA, telling your genes when to switch on and off — accumulates in predictable patterns as you age. Dr. Steve Horvath, a biostatistician at UCLA, discovered that by mapping these methylation patterns across hundreds of specific sites on the genome, you can calculate a biological age that often diverges significantly from your chronological age.¹

Think of the epigenetic clock as your body’s internal mileage meter — not how many years you’ve been alive, but how hard those years have been driven. Two 45-year-olds can have the same birthday and completely different biological ages depending on how they’ve lived, trained, recovered, and fueled themselves.

The Horvath clock measures this mileage. And until recently, most scientists assumed it only ran in one direction — forward.

Your chronological age is your birthday. Your biological age is what your cells have lived through.

Why This Matters for Athletes

For the committed lifter, this isn’t abstract philosophy — it’s performance data. Emerging research suggests¹ that individuals with an elevated biological age relative to their chronological age show markers consistent with accelerated inflammation, blunted hormonal response, and slower tissue repair.

Translation: your cells being “older” than you are is just chronic inflammation and blunted recovery dressed up in molecular language. That’s your world.

The Genesis: Dr. Fahy and the TRIIM Trial

Dr. Gregory Fahy, Chief Scientific Officer at Intervene Immune, had a hypothesis that went against the accepted trajectory of aging science: what if the thymus — the immune gland that shrinks as you age, gutting your body’s capacity to produce fresh T-cells — could be partially regenerated?¹

The thymus is the body’s immune training ground — tight junctions of biological activity where naive immune cells are educated and armed before deployment. By your mid-twenties, it’s already beginning to involute, replacing functional tissue with fat. By 40, most of it is gone. By 60, it’s largely a ghost organ doing a fraction of its original job.

Fahy’s earlier research suggested that recombinant human growth hormone (rhGH) could reverse this involution — actually regrowing functional thymic tissue. The TRIIM trial (Thymic Regeneration, Immunorestoration, and Insulin Mitigation) was designed to test this hypothesis in a real human cohort, while also monitoring what happened to participants’ biological age markers along the way.¹

The unexpected finding: as thymic tissue regenerated across the trial’s participants, the Horvath epigenetic clock appeared to run in reverse.

Not just pause — reverse. That was the headline that landed in Aging Cell in 2019 and launched a thousand longevity podcasts.

The TRIIM Protocol: The Trio Breakdown

The TRIIM protocol wasn’t a simple single-agent intervention. It was a carefully constructed three-way stack — and the rationale behind each component matters if you want to understand what you’re actually looking at when you evaluate the results.

Agent 1: Recombinant Human Growth Hormone (rhGH)

rhGH — the synthetic version of the growth hormone your pituitary naturally produces — was the primary driver of thymic regeneration in the protocol. GH receptors are abundant in thymic tissue, and prior animal and human studies had demonstrated that GH can reverse thymic involution and restore T-cell output.¹

Think of GH here as the construction foreman — it signals tissues to rebuild, regenerate, and restore functional architecture. For the thymus specifically, it doesn’t just slow the involution; it appears to actively reverse it, encouraging the gland to produce new functional tissue rather than accumulating more fat.

The critical caveat: rhGH is not a casual supplement. It sits firmly in prescription territory, and its administration in the TRIIM trial was medically supervised. It also comes with real metabolic consequences — including potential insulin resistance, which is exactly why the other two agents in the stack existed.

Agent 2: DHEA (Dehydroepiandrosterone)

DHEA — dehydroepiandrosterone — is the most abundant steroid hormone in the human body and a precursor to both testosterone and estrogen. Its role in the TRIIM stack was strategic: cortisol buffering.¹

GH administration can shift the cortisol-to-DHEA ratio in ways that create a pro-catabolic hormonal environment. Since DHEA is often described as cortisol’s counter-weight — think of it as the spotter who keeps cortisol from dropping the barbell on your testosterone — supplementing it during an rhGH protocol helps maintain hormonal balance and protect anabolic tone.

DHEA is available as an over-the-counter supplement in the US, but the doses used in clinical protocols are typically higher than what’s on the average health-food-store shelf, and their effects are highly individual.

Agent 3: Metformin

Metformin — a first-line oral medication for type 2 diabetes — was included as the insulin mitigation agent in the stack.¹ rhGH is notorious for inducing insulin resistance as a side effect, and Fahy’s design called for pharmaceutical coverage of that risk.

Metformin activates AMPK — think of it as the cellular fuel gauge that shifts the body toward fat oxidation and away from excess glucose storage — and has attracted significant longevity research interest independent of its diabetes application. In the TRIIM context, it wasn’t the headline agent; it was the safety net keeping the metabolic environment stable.

Worth noting for the gym community: metformin has a contested relationship with exercise adaptation. Some research suggests it may blunt certain training-induced mitochondrial adaptations. This tension is relevant context for Part 2 of this series.

The TRIIM stack isn’t a supplement protocol — it’s a medically supervised intervention. Each agent is doing a specific job, and removing any one of them changes the equation entirely.

The Matchback Caveat: Questioning the Black Box

Here’s where I need to pump the brakes — and I mean this in the most constructive possible way, because the results of the TRIIM trial are genuinely exciting and deserve scrutiny proportional to their significance.

Is the epigenetic reversal as clean as the headlines suggested, or is there a methodological black box we should be looking at more carefully? Let’s dig in.

The Matchback Problem

The TRIIM trial did not include a control group — a critical structural limitation.¹ Nine participants. No placebo arm. No randomization. To estimate what “natural aging” would have looked like in the same individuals over the same period, the researchers used a statistical technique called matchback analysis — essentially modeling a hypothetical control group by matching participants to historical data and projecting their expected epigenetic trajectory.

The Skeptic’s Question: Is a modeled control group a reliable substitute for a real one?

The answer is: not always. Matchback modeling introduces assumptions about population-level aging trajectories that may or may not apply to the specific individuals in the trial. If the nine participants in TRIIM were already biological age outliers in any direction — due to lifestyle, genetics, or selection bias — the matchback model’s baseline projection could be systematically off in ways that artificially inflate or deflate the apparent reversal signal.

Correlation vs. Mechanistic Causation

The second black-box concern is mechanistic: the TRIIM trial demonstrated a correlation between the three-agent intervention and changes in epigenetic clock readings. It did not — and by its design, could not — isolate which agent was responsible for which component of the observed change, or confirm that the hormonal shifts caused the epigenetic changes rather than simply accompanying them.

This is the correlation-doesn’t-equal-causation problem dressed in cutting-edge molecular biology clothing. The data is real. The observed signal is real. But the mechanistic chain — from rhGH to thymic regrowth to epigenetic reversal — remains an hypothesis supported by correlation, not yet proven by the kind of mechanistic RCT that would let you draw causal arrows with confidence.

None of this invalidates the findings. It contextualizes them. Think of the TRIIM data as a compelling training log entry rather than a peer-reviewed 10-year longitudinal study. It tells you something important. It doesn’t tell you everything.

The Results: What the Data Actually Showed

With the methodological caveat clearly on the table, let’s look at what the TRIIM trial actually found — because it’s genuinely remarkable, even with the caveats attached.

The primary results published in Aging Cell showed:

• Epigenetic age reversal: The Horvath clock readings of participants showed an average reversal of approximately 2.5 years of biological age over the course of the one-year trial.¹ Each participant’s epigenetic age ended lower than it had begun — not just unchanged, not just slowed, but reversed.
• Thymic regeneration confirmed: MRI imaging confirmed measurable increases in thymic tissue density and functional volume — direct structural evidence that the gland was responding to the rhGH component of the protocol.¹
• Immune system improvements: Participants showed signs of immunorestoration — increased naive T-cell output consistent with a more youthful immune profile.¹
• No significant safety signals: The protocol was well-tolerated across participants without severe adverse events reported during the trial period.

These are not small findings. A 2.5-year reversal in Horvath clock readings in a one-year intervention — if reproducible — would represent one of the most significant demonstrations of biological age modulation in human research history.

The Crucial Limitation

Nine participants. One year. No control group. No randomized replication. No long-term follow-up data on whether the effect persists or fades.¹

This is a pilot study — and the authors say as much themselves. It was designed to establish proof of concept and signal safety for a larger, more rigorous trial. It does that job well. What it cannot do is serve as a clinical standard, a universal protocol recommendation, or definitive proof that biological age reversal is achievable for every human being who follows the same three-agent stack.

The honest framing: emerging research suggests this is a promising signal worth pursuing. The honest caveat: more large-scale, long-term, randomized trials are needed before we can say definitively what this means for anyone outside those nine individuals.

Nine people. One year. No control group. Remarkable findings — and real limitations. Both things are true.

A Blueprint, Not a Prescription

So where does this leave us?

The TRIIM trial is best understood as a blueprint — a proof-of-concept that outlines the architecture of a potential biological age reversal protocol without yet providing the kind of replication, sample size, and longitudinal data needed to call it a clinical standard.

It answers a critical question: Is this theoretically possible? The answer appears to be yes. It does not yet answer: Is this safe, reproducible, and practical for a general population? That’s where the science is heading next.

What it does tell us — with reasonable confidence — is that the epigenetic clock is not a fixed escalator running in one direction. The biological age of your cells is not a sentence; it’s a variable. And the factors that influence it — hormonal environment, immune function, inflammation status, metabolic health — are exactly the levers that committed lifters are already pulling, just at the lifestyle level rather than the pharmaceutical level.

Which brings us to the question that makes this relevant to your training: what does the evidence look like when we zoom out from the TRIIM protocol to the individual physiological factors it was targeting? That’s Part 2 of this series.

See Also: Battling Stress — How Cortisol Affects Your Testosterone and Recovery (Coming Soon)

See Also: Metabolic Endotoxemia — The Silent Inflammation Blocking Your Fitness Gains

Actionable Takeaways for the Evidence-Driven Lifter

You’re not going to walk out of this article and source pharmaceutical rhGH. That’s not the point. But the TRIIM trial does surface some actionable signal even for the gym-focused reader who wants to understand biological aging — and start moving the right levers:

Understand Your Biological Age Baseline

• Epigenetic age testing is now commercially available through labs like TruDiagnostic and Elysium Health. If you’re serious about longevity alongside performance, this is a meaningful data point worth having.
• Track it over time — not as a single reading, but as a trend you can correlate with lifestyle changes.

Protect Your GH Axis — Naturally

• The TRIIM trial used pharmaceutical rhGH because natural GH production declines significantly with age. But for lifters under 50 with functional pituitary health, the lifestyle levers that support natural GH output are powerful: deep sleep (GH pulses during slow-wave sleep), resistance training (compound movements with progressive overload drive significant GH release), and strategic fasting protocols.
• Protect your sleep like you protect your training. GH is manufactured in the dark.

Manage Your Cortisol-to-DHEA Ratio

• DHEA was included in TRIIM specifically to buffer the cortisol-raising effects of rhGH. Even without pharmaceutical intervention, the cortisol-DHEA balance matters for every lifter managing training stress, work load, and recovery.
• Chronic stress, under-recovery, and overtraining all push this ratio in the wrong direction. Lifestyle management of cortisol isn’t a soft skill — it’s a performance variable with real epigenetic implications.

Optimize Metabolic Health as a Foundation

• Metformin’s role in TRIIM was insulin mitigation — keeping blood glucose and insulin sensitivity in check during GH administration. You can pursue those same metabolic outcomes through dietary strategy: limiting refined carbohydrates, prioritizing fiber and whole foods, and maintaining the insulin sensitivity that comes with consistent resistance training.
• Metabolic health isn’t just a cardiovascular metric — it’s increasingly understood as a key variable in biological aging. Your macros and your epigenetic clock are more connected than you think.

Part 2 of 3: The Biological Age Series: DHEA and the Aromatase Trap

Part 3 of 3: This Biological Age Series: DIM, Estrogen, and Regulation

Research & References

¹ Fahy, G. M., Brooke, R. T., Watson, J. P., Good, Z., Varelas, I. S., Piccirillo, S., … & Horvath, S. (2019). Reversal of epigenetic aging and immunosenescent trends in humans. Aging Cell, 18(6), e13028. — The primary TRIIM trial publication. A pilot study (n=9) demonstrating that a one-year protocol of rhGH, DHEA, and metformin was associated with an average 2.5-year reversal in Horvath epigenetic clock readings, alongside confirmed thymic tissue regeneration. Authors acknowledge the absence of a randomized control group as a primary limitation.

Kyle Hansen Fitness  |  Science-driven health and nutrition insights for stronger bodies and longer lives.